Duvelisib was the 2nd PI3K inhibitor approved by the FDA, also based on a phase III randomized trial.130 The efficacy and basic safety profile in the drug appear similar with Individuals of idelalisib, Otherwise slightly beneficial. Regarding alternative BTK inhibitors, there are several solutions in improvement, but only acalabrutinib is authorise